|
Market Closed -
Euronext Paris
16:55:00 08/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 141.50 EUR | -2.41% |
|
-0.42% | +18.91% |
| 10-08 | Tesco cashes in, OPmobility takes a hit |  |
| 09-25 | US FDA approves Mirum's drug for rare bone disorder | RE |
MarketScreener Strategies
Search
 | Ipsen: Incorporating solid H1 operational performance + guidance upgrade | September 17, 2026 at 04:19 pm |
| Ipsen: Another quarterly beat; 2026 guidance upgraded | July 30, 2026 at 02:49 pm |
 | Ipsen: Reassessing mid-term risks | July 06, 2026 at 01:00 pm |
| Ipsen: Beneficiary of favourable product mix and imminent readouts | May 27, 2026 at 08:30 am |
| Ipsen: Opened the year with encouraging traction | April 23, 2026 at 10:04 pm |
| Ipsen: Markets applaud strong finish to 2025 and better-than-expected 2026 outlook | February 12, 2026 at 02:32 pm |
| Ipsen raises 2025 outlook after stronger Somatuline | November 17, 2025 at 01:10 pm |
No results match your criteria
- Stock Market
- Stocks
- IPN Stock
- News Ipsen
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
